← All trials
NCT05512910
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 13, 2022
- Primary completion
- Nov 30, 2024
- Completion date
- Nov 30, 2024
- First posted
- Aug 23, 2022
- Last posted
- Dec 16, 2022
- Enrollment
- 90
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Xijing HospitalLead sponsor
- First People's Hospital of XianyangCollaborator
- Xi’an Gaoxin HospitalCollaborator
- Jiao Tong UniversityCollaborator
- Xi'an XD Group HospitalCollaborator
- Xijing HospitalReponsible party - principal investigator
- Xijing HospitalSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.